Thalidomide in the management of Recurrent Aphthous Ulcerations in patients who are HIV-positive: A review and case reports

Special Care in Dentistry

Volumn 25, Issue 5, 2005, Pages 236-241

  Shetty, Kishore ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Corticosteroids; Human Immunodeficiency Virus (HIV); Recurrent Aphthous Ulcers (RAU); Thalidomide

Indexed keywords

EID: 27344444440     PISSN: 02751879     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1754-4505.2005.tb01656.x     Document Type: Review

References (23)

1. Shashy RG, Ridley MB. Aphthous ulcers: a difficult clinical entity. Am J Otolryngol 2000; 21:389-93.
2. MacPhail LA, Greenspan, JS. Oral ulceration in HIV infection: investigation and pathogenesis. Oral Diseases 1997; 3(supplement 1):190-3.
3. JAMA HIV/AIDS Resource Center. Thalidomide. Retrieved Jan 26, 2004, from http://www.ama-assn.org/special/hiv/newsline/briefing/thalido.htm
4. Zakrzewska JM, Robinson P, Williams IG. Severe oral ulceration in patients with HIV infection: a case series. Oral Diseases 1997; 3(supplement 1):194-6.
5. Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis 2001; 68:201-06.
6. Casiglia TM. Recurrent aphthous stomatitis: etiology, diognosis and treatment. Gen Dent 2002; 50:157-66.
7. Bonnetblanc JM, Royer C, Bedane C. Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology 1996; 193:321-3.
8. Soler RA, Howard M, Brink NS, et al. Regression of AIDS-related Kaposis sarcoma during therapy with thalidomide. Clin Infect Dis 1996; 23:501-3.
9. Amato RJ. Thalidomide: an antineoplastic agent. Curr Oncol Rep 2002; 4:56-62.
10. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor (alpha) production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
11. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocytes sub-populations in the circulating blood of healthy males. LEPR Rev 1985; 56:35-9.
12. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
13. Buno IJ, Huff JC, Weston WL, et al. Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4 and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol 1998; 134:827-31.
14. Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide alter dosing healthy male volunteers. Drug Metab Dispos 1989; 17:402-5,
15. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacology 1965; 25:325-37.
16. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacology 1965; 25:338-51.
17. Fabro S, Schumacher H, Smith RL, et al. The metabolism of thalidomide: some biological effects of thalidomide and its metabolite. Br J Pharmacology 1965; 25:352-62.
18. Jacobsen JM, Spitzler J, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. J Infect Dis 1999; 180:61-7.
19. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatis. Arch Dermatol 1990; 126:923-7.
20. Clemmenson OJ, Olsen PZ, Anderson KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120:338-41.
21. Aweeka F, Trapnell C, et al. Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG Protocol 251. J Clin Pharmacology 2001; 41:1091-7.
22. Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan MED Surg 1998; 17(4):231-42.
23. Powcll RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994; 70:901-4.